Isoxsuprine

Identification

Name
Isoxsuprine
Accession Number
DB08941
Type
Small Molecule
Groups
Approved, Withdrawn
Description

A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Isoxsuprine hydrochlorideV74TEQ36CO579-56-6QVPSGVSNYPRFAS-BQZDIUEZSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VasodilanTablet10 mg/1OralBristol Myers Squibb1996-01-012007-07-31Us
VasodilanTablet20 mg/1OralBristol Myers Squibb1997-01-012007-06-30Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralVedco Dba Valdar2011-08-23Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralPhysicians Total Care, Inc.1996-06-122011-06-30Us
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralEci Pharmaceuticals Llc2011-08-23Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralBI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY2011-06-02Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralBi-Coastal Pharmaceutical Corporation2011-06-02Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (10 mg/1)TabletOralEci Pharmaceuticals Llc2011-06-02Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (10 mg/1)TabletOralBI-COASTAL PHARMA INTERNATIONAL LIMITED LIABILITY COMPANY2011-06-02Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (10 mg/1)TabletOralBi-Coastal Pharmaceutical Corporation2011-06-02Not applicableUs
Isoxsuprine HydrochlorideIsoxsuprine hydrochloride (20 mg/1)TabletOralVista Pharmaceuticals, Inc.1997-09-19Not applicableUs
Categories
UNII
R15UI3245N
CAS number
395-28-8
Weight
Average: 301.386
Monoisotopic: 301.167793605
Chemical Formula
C18H23NO3
InChI Key
BMUKKTUHUDJSNZ-HBUWYVDXSA-N
InChI
InChI=1S/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3/t13-,14-,18-/m1/s1
IUPAC Name
4-[(1S,2R)-1-hydroxy-2-{[(2R)-1-phenoxypropan-2-yl]amino}propyl]phenol
SMILES
C[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C1=CC=C(O)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Isoxsuprine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-isobutyl-1-methyl-7H-xanthineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with 3-isobutyl-1-methyl-7H-xanthine.
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Isoxsuprine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Isoxsuprine.
6-O-benzylguanineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with 6-O-benzylguanine.
7-DeazaguanineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with 7-Deazaguanine.
7,9-DimethylguanineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with 7,9-Dimethylguanine.
8-azaguanineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with 8-azaguanine.
8-chlorotheophyllineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with 8-chlorotheophylline.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
11779629
PubChem Substance
310264908
ChemSpider
9954311
Wikipedia
Isoxsuprine
ATC Codes
C04AA01 — Isoxsuprine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral20 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0507 mg/mLALOGPS
logP2.06ALOGPS
logP2.56ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)9.65ChemAxon
pKa (Strongest Basic)9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area61.72 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity86.64 m3·mol-1ChemAxon
Polarizability34.12 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
Phenoxy compounds / Phenol ethers / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Phenylpropane / Phenol ether / Phenoxy compound / Alkyl aryl ether / Phenol / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Secondary alcohol / 1,2-aminoalcohol / Secondary amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on May 26, 2014 15:29 / Updated on November 02, 2018 08:53